Mohammad Taghi Hedayati Goudarzi

Mohammad Taghi Hedayati Goudarzi

Auto-generated profile, based on publicly available information

Mohammad Taghi Hedayati Goudarzi

Cardiology Department, Babol University of Medical Science, Babol, Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2024 in BioMedical Engineering OnLine
Verified
Journal Article
Open access
PDF file
HZHadi Zare-Zardini
Hadi Zare-Zardini
MHMohammad-Taghi Hedayati-Goudarzi
Mohammad-Taghi Hedayati-Goudarzi
AAAmeneh Alizadeh
Ameneh Alizadeh
FSFatemeh Sadeghian-Nodoushan
Fatemeh Sadeghian-Nodoushan
HSHossein Soltaninejad
Hossein Soltaninejad
Chemotherapy-induced cardiotoxicity is a significant concern in cancer treatment, as certain chemotherapeutic agents can have adverse effects on the cardiovascular system. This can lead to a range of cardiac complications, including heart failure, arrhythmias, myocardial dysfunction, pericardial complications, and vascular toxicity. Strategies to mitigate chemotherapy-induced cardiotoxicity may include the use of cardioprotective agents (e.g., dexrazoxane), dose adjustments, alternative treatment regimens, and the implementation of preventive measures, such as lifestyle modifications and the management of cardiovascular risk factors. Ginsenosides, the active compounds found in ginseng (Panax ginseng), have been studied for their potential cardioprotective effects in the context of chemotherapy-induced cardiotoxicity. In this review, we investigate the cardioprotective effect of ginsenosides in chemotherapy-induced cardiotoxicity. Ginsenosides have been shown to possess potent antioxidant properties, which can help mitigate the oxidative stress and inflammation associated with chemotherapy-induced cardiac injury. They can modulate the expression of antioxidant enzymes and reduce the production of reactive oxygen species, thereby protecting cardiomyocytes from damage. Ginsenosides can also inhibit apoptosis (programmed cell death) of cardiomyocytes, which is a key mechanism underlying chemotherapy-induced cardiotoxicity. Modulation of ion channels, improvement of lipid profiles, anti-platelet and anti-thrombotic effects, and promotion of angiogenesis and neovascularization are another important mechanisms behind potential effects of ginsenosides on cardiovascular health. Ginsenosides can improve various parameters of cardiac function, such as ejection fraction, fractional shortening, and cardiac output, in animal models of chemotherapy-induced cardiotoxicity. The cardioprotective effects of ginsenosides have been observed in preclinical studies using various chemotherapeutic agents, including doxorubicin, cisplatin, and 5-fluorouracil. However, more clinical studies are needed to fully elucidate the therapeutic potential of ginsenosides in preventing and managing chemotherapy-induced cardiotoxicity in cancer patients.

6 December 2021 in Journal of Cardiovascular and Thoracic Research
Verified
Journal Article
Open access
PDF file
FJFarzad Jalali
Farzad Jalali
FHFarbod Hatami
Farbod Hatami
MSMehrdad Saravi
Mehrdad Saravi
IJIraj Jafaripour
Iraj Jafaripour
MHMohammad Taghi Hedayati
Mohammad Taghi Hedayati
NZnaghmeh ziaei
naghmeh ziaei
Introduction: To address cardiovascular (CV) complications and their relationship to clinical outcomes in hospitalized patients with COVID-19. Methods: A total of 196 hospitalized patients with COVID-19 were enrolled in this retrospective single-center cohort study from September 10, 2020, to December 10, 2020, with a median age of 65 years (IQR, 52-77). Follow-up continued for 3 months after hospital discharge. Results: CV complication was observed in 54 (27.6%) patients, with arrhythmia being the most prevalent (14.8%) followed by myocarditis, acute coronary syndromes, ST-elevation myocardial infarction, cerebrovascular accident, and deep vein thrombosis in 15 (7.7%), 12 (6.1%), 10(5.1%), 8 (4.1%), and 4 (2%) patients, respectively. The proportion of patients with elevated high-sensitivity troponin I, N-terminal pro-B-type natriuretic peptide, left ventricular diastolic dysfunction, and heart failure with preserved ejection fraction was greater in the CV complication group. Severe forms of COVID-19 comprised nearly two-thirds (64.3%) of our study population and constituted a significantly higher share of the CV complication group members (75.9%vs 59.9%; P=0.036). Intensive care unit admission (64.8% vs 44.4%; P=0.011) and stay (5.5days vs 0 day; P=0.032) were notably higher in patients with CV complications. Among 196patients, 50 died during hospitalization and 10 died after discharge, yielding all-cause mortality of 30.8%. However, there were no between-group differences concerning mortality. Age, heart failure, cancer/autoimmune disease, disease severity, interferon beta-1a, and arrhythmia were the independent predictors of all-cause mortality during and after hospitalization. Conclusion: CV complications occurred widely among COVID-19 patients. Moreover,arrhythmia, as the most common complication, was associated with increased mortality.

1 January 2023 in Canadian Journal of Infectious Diseases and Medical Microbiology
Verified
Journal Article
Open access
PDF file
SESeyed Parsa Eftekhar
Seyed Parsa Eftekhar
MSMahdi Sepidarkish
Mahdi Sepidarkish
PMParviz Amri Maleh
Parviz Amri Maleh
IJIraj Jafaripour
Iraj Jafaripour
MHMohammad Taghi Hedayati
Mohammad Taghi Hedayati
NZnaghmeh ziaei
naghmeh ziaei
Purpose. Maintaining the proper fluid balance is a fundamental step in the management of hospitalized patients. The current study evaluated the impact of negative fluid balance on outcomes of patients with confirmed COVID‐19. Methods. We considered the negative fluid balance as a higher output fluid compared to the input fluid. The fluid balance was categorized into four groups (group 4: −850 to −500 ml/day; group 3: −499 to −200 ml/day, group 2: −199 to 0 ml/day, and group 1 : 1 to 1000 ml/day) and included ordinally in the model. The outcomes were all‐cause mortality, length of hospitalization, and improvement in oxygen saturation. Results. The fluid balance differed significantly among nonsurvivors and survivors (MD: −317.93, 95% CI: −410.21, −225.69, and p < 0.001). After adjusting for potential confounders, there was a significantly lower frequency of mortality in patients with negative fluid balance compared to the controls (aRR: 0.69, 95% CI: 0.57, 0.84, and p < 0.001). Similarly, the length of hospitalization was significantly shorter in the negative fluid balance group in comparison to the control group (aMD: −1.01, 95% CI: −1.74, −0.28, and p = 0.006). Conclusion. We determined that the negative fluid balance was associated with favorable outcomes in COVID‐19 patients. The negative fluid balance was associated with the reduced mortality rate and length of hospitalization as well as improvement in oxygen saturation. Moreover, the NT‐proBNP >781 pg/mL and fluid balance >−430 mL might be the predictors for positive fluid balance and mortality, respectively.

27 March 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
MGMohammad Taghi Hedayati Godarzi
Mohammad Taghi Hedayati Godarzi
MRMohamad Rashid
Mohamad Rashid
SASaeed Abrotan
Saeed Abrotan
MFMarjan Fallah
Marjan Fallah
MSMehdi Seifi
Mehdi Seifi
NNNovin Nikbakhsh
Novin Nikbakhsh
Myasthenia gravis (MG) is a rare autoimmune neuromuscular disorder in which autoantibodies impair neuromuscular junctions. MG can be associated with thymoma and with antibodies to the acetylcholine receptor (AChR), and is less commonly associated with antibodies to muscle-specific tyrosine kinase (MuSK). Treatment of AChR antibody-positive myasthenia gravis with the cholinesterase inhibitor, pyridostigmine, has known cardiac conduction side effects. Some reports indicate these cardiac effects, including bradyarrhythmias, occur more often with MuSK-ab positive MG. This report is of a 62-year-old man with recent onset muscle-specific tyrosine kinase (MuSK)-negative thymomatous myasthenia gravis presenting with bradycardia due to pyridostigmine-associated atrioventricular (AV) block. A 62-year-old man presented with fluctuating muscle weakness, unilateral ptosis, mild dyspnea, and mild dysphagia. Laboratory testing was positive for acetylcholine receptor antibodies (AChR-ab), but negative for MuSK antibodies. Due to his symptoms, treatment with intravenous immunoglobulin (IVIg) and pyridostigmine was initiated. Mediastinal computed tomography scan (CT scan) revealed a thymoma. During thymectomy surgery, the patient experienced intraoperative asystole. After he was stabilized, episodes of high-degree atrioventricular (AV) block were seen on postoperative ambulatory rhythm monitoring. Therefore, a permanent pacemaker (PPM) was implanted before repeat thymectomy, which was performed without complications Histopathological examination of the thymic tissue demonstrated a type B1 thymoma. This report has highlighted the importance of accurate diagnosis of MG and its autoimmune subtypes, and if treatment is required with pyridostigmine, the importance of follow-up and electrocardiographic monitoring to ensure the rapid diagnosis and management of cardiac conduction abnormalities, even if they are MuSK antibody-negative.

13 November 2023 in Cardiology Research and Practice
Verified
Journal Article
Open access
PDF file
MGMohammad Taghi Hedayati Goudarzi
Mohammad Taghi Hedayati Goudarzi
MMMaryam Moradi
Maryam Moradi
SASaeed Abrotan
Saeed Abrotan
MSMehrdad Saravi
Mehrdad Saravi
HSHoda Shirafkan
Hoda Shirafkan
HOHossein Salehi Omran
Hossein Salehi Omran
Background. Hypertrophic cardiomyopathy (HCM) has different complications such as cardiac arrhythmia and sudden cardiac death (SCD). Insertion of an implantable cardioverter defibrillator (ICD) is recommended for HCM patients who are at high risk of SCD and malignant arrhythmias, despite having their own potential complications. Hypothesis. We aimed to investigate the prevalence of different complications of ICD insertion and the impact of the potential influential baseline characteristics in a one-year follow-up period. Methods. This was a retrospective study with a total of 71 HCM patients with ICD insertion. We evaluated the prevalence of different complications of ICD implantation and the impact of baseline characteristics on the occurrence of ICD complications using multivariate regression analysis in three 4-month periods. Results. In a one-year follow-up, 13 patients (18.3%) experienced at least one of the complications including pneumothorax, lead failure, ICD infection, inappropriate shocks, perforation, and upper limb deep vein thrombosis (DVT) with no mortality. Inappropriate shocks were reported as the most common (11.3%) complication during this period, with a gradual increase in the second (4.2%) and third (5.6%) follow-up sessions. Among all of the baseline characteristics that were investigated in this study, a positive history of hypertension was the only risk factor with significant impact on the occurrence of complications ( = 0.01). Conclusion. We demonstrated the occurrence of complications during a one-year follow-up as 18.3% in HCM patients with ICD insertion. A positive history of hypertension was the only baseline characteristic affecting the occurrence of complications, and inappropriate shocks were the most common complication.

11 March 2025
Verified
Journal Article
Open access
HOHossein Salehi Omran
Hossein Salehi Omran
ABAmir Balouchzadeh
Amir Balouchzadeh
SDSina Dolatshahi
Sina Dolatshahi
SASaeed Abrotan
Saeed Abrotan
MOMohammad Taghi Salehi Omran
Mohammad Taghi Salehi Omran
MGMohammad Taghi Hedayati Goudarzi
Mohammad Taghi Hedayati Goudarzi
Patients with moderate to severe chronic heart failure (CHF) are at high risk for cardiac mortality. Cardiac resynchronization therapy with defibrillators (CRT-D) as a potentially beneficial option can improve the clinical outcomes of such patients. We conducted a single-arm clinical trial in which 48 patients with moderate to severe CHF were investigated regarding the beneficial outcome of CRT-D insertion. All participants were evaluated regarding different functional and echocardiographic factors including New York Heart Association (NYHA) functional class (FC), left ventricular ejection fraction (LVEF), mitral regurgitation (MR) as well as left ventricular end-systolic (LVESD) and end-diastolic (LVEDD) before and one month after the procedure. Furthermore, we investigated the influence of different variables including age, gender, and comorbidities on the aforementioned clinical and echocardiographic factors. Of the 48 CHF patients included in our study, 24 (50%) were males and 24 (50%) were females. The mean ± standard deviation (range) of the participants’ age was 55.6±6.5 (40-69) years. CRT-D insertion significantly improved all functional and echocardiographic factors in CHF patients. The participants had a mean±standard deviation (range) LVEF of 22.1±5.8% (10-30%) before CRT-D insertion. A follow-up echocardiography performed one month after the implantation of CRT-D demonstrated a significant increase in LVEF to 27.1±5.5% (15-38%) (p<0.001). Additionally, echocardiography conducted one month after CRT-D insertion showed a reduction of LVESD from 6.8±0.5 cm (5.8-7.4 cm) to 6.2±0.5 cm (5.3-7.3 cm) (p<0.001). There is prominent evidence for CRT-D insertion in reducing symptoms of heart failure as well as improving different echocardiography variables in patients with moderate to severe CHF.